SIX · BION.SW
BB Biotech AG
CHF 51.20+CHF 1.00 (+1.99%)
BB Biotech AG’s quoted price sits in the upper half of its reported 52-week range, 10.18% below the high.
Loading market information…
SIX · KURN.SW · CHF
Stock price, earnings
Quote as of Oct 29, 2026, 04:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
Kuros Biosciences AG’s quoted price sits in the lower half of its reported 52-week range, 35.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Kuros Biosciences AG’s next earnings report is currently expected on Mar 3, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kuros Biosciences AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2023 | Aug 23, 2023 | -CHF 0.14 | CHF 12.87M+36.87% vs estimate |
|---|
| Q4 2022 | Mar 15, 2023 | -CHF 0.32 | CHF 7.56M-14.09% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 51.20+CHF 1.00 (+1.99%)
BB Biotech AG’s quoted price sits in the upper half of its reported 52-week range, 10.18% below the high.
CHF 76.30+CHF 0.10 (+0.13%)
SKAN Group AG’s quoted price sits in the upper half of its reported 52-week range, 1.42% below the high.
CHF 43.40-CHF 0.30 (-0.69%)
PolyPeptide Group AG’s quoted price sits in the upper half of its reported 52-week range, 13.37% below the high.
CHF 4.58-CHF 0.01 (-0.22%)
Idorsia Ltd’s quoted price sits in the lower half of its reported 52-week range, 39.39% below the high.
CHF 97.30+CHF 2.00 (+2.1%)
Medartis Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.92% below the high.
CHF 14.20-CHF 0.15 (-1.05%)
Aevis Victoria S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
CHF 58.70CHF 0.00 (0.0%)
Cosmo Pharmaceuticals N.V.’s quoted price sits in the lower half of its reported 52-week range, 54.64% below the high.
CHF 71.50-CHF 1.90 (-2.59%)
Basilea Pharmaceutica AG’s quoted price sits in the upper half of its reported 52-week range, 5.67% below the high.
